Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Erika Matsusita"'
Autor:
Daisuke Ohgiya, Yukari Shirasugi, Erika Matsusita, Eri Kikkawa, Yoshiaki Ogawa, Ken Ohmachi, Shinichiro Machida, Kiyoshi Ando, Hiroshi Kawada, Ryujiro Hara, Makoto Onizuka, Hiromichi Matsushita, Hiromichi Murayama, Yoshihiko Nakamura
Publikováno v:
International journal of hematology. 106(5)
A recent study reported that treatment-free remission (TFR) of chronic myeloid leukemia (CML) after dasatinib (Das) treatment was significantly associated with natural killer (NK) cell proliferation in the peripheral blood. However, biomarkers to pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce13c0a48fc9a0a6f16625023215b33
https://pubmed.ncbi.nlm.nih.gov/28795321
https://pubmed.ncbi.nlm.nih.gov/28795321
Autor:
Yoshihiko Nakamura, Ryujiro Hara, Hiroshi Kawada, Daisuke Ogiya, Erika Matsusita, Hiromichi Murayama, Yoshiaki Ogawa, Yukari Shirasugi, Makoto Onizuka, Kiyoshi Ando, Ken Omachi, Eri Kikkawa
Publikováno v:
Blood. 128:3091-3091
Dasatinib (DA) is a tyrosine kinase inhibitor (TKI), and is approved for the treatment of naïve and relapsed/refractory Philadelphia chromosome positive leukemia. DA is a potent and multi-target TKI, and a part of patients treated with DA are report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac896badd97806d72356d4c047a8584f
https://doi.org/10.1182/blood.v128.22.3091.3091
https://doi.org/10.1182/blood.v128.22.3091.3091